Maxcyte Stock Buy Hold or Sell Recommendation
| MXCT Stock | USD 3.55 0.10 2.90% |
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding MaxCyte is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell MaxCyte given historical horizon and risk tolerance towards MaxCyte. When Macroaxis issues a 'buy' or 'sell' recommendation for MaxCyte, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out MaxCyte Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide. Note, we conduct extensive research on individual companies such as MaxCyte and provide practical buy, sell, or hold advice based on investors' constraints. MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
MaxCyte |
Execute MaxCyte Buy or Sell Advice
The MaxCyte recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on MaxCyte. Macroaxis does not own or have any residual interests in MaxCyte or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute MaxCyte's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
MaxCyte Trading Alerts and Improvement Suggestions
| MaxCyte generated a negative expected return over the last 90 days | |
| MaxCyte has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 41.29 M. Net Loss for the year was (37.92 M) with profit before overhead, payroll, taxes, and interest of 39.16 M. | |
| MaxCyte currently holds about 240.89 M in cash with (21.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37. | |
| MaxCyte has a poor financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: This MaxCyte Insider Increased Their Holding In The Last Year |
MaxCyte current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. MaxCyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. MaxCyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
MaxCyte Returns Distribution Density
The distribution of MaxCyte's historical returns is an attempt to chart the uncertainty of MaxCyte's future price movements. The chart of the probability distribution of MaxCyte daily returns describes the distribution of returns around its average expected value. We use MaxCyte price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of MaxCyte returns is essential to provide solid investment advice for MaxCyte.
| Mean Return | -0.17 | Value At Risk | -5.56 | Potential Upside | 5.31 | Standard Deviation | 3.23 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of MaxCyte historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
MaxCyte Stock Institutional Investors
The MaxCyte's institutional investors refer to entities that pool money to purchase MaxCyte's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Portolan Capital Management, Llc | 2024-06-30 | 1.7 M | Swedbank Ab | 2024-09-30 | 1.6 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 1.4 M | Chevy Chase Trust Holdings, Inc. | 2024-09-30 | 1.3 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.2 M | Ameriprise Financial Inc | 2024-06-30 | 1.1 M | Northern Trust Corp | 2024-09-30 | 860.3 K | Silvercrest Asset Management Group Llc | 2024-06-30 | 708.2 K | Centerbook Partners Lp | 2024-09-30 | 585.1 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 9.3 M | Cadian Capital Management Lp | 2024-09-30 | 8.2 M |
MaxCyte Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (1.9M) | (890.6K) | (1.4M) | (3.5M) | 697K | 731.9K | |
| Change In Cash | 4.0M | 3.5M | 29.0M | (36.7M) | 35.4M | 37.2M | |
| Free Cash Flow | (10.1M) | (10.9M) | (14.5M) | (33.3M) | (25.4M) | (24.1M) | |
| Depreciation | 613.5K | 1.0M | 1.4M | 2.7M | 4.2M | 4.4M | |
| Other Non Cash Items | 76.9K | 101.6K | 57K | (2.5M) | (5.7M) | (5.4M) | |
| Capital Expenditures | 1.3M | 2.1M | 3.8M | 18.5M | 3.7M | 2.9M | |
| Net Income | (12.9M) | (11.8M) | (19.1M) | (23.6M) | (37.9M) | (36.0M) | |
| End Period Cash Flow | 15.2M | 18.8M | 47.8M | 11.1M | 46.5M | 48.8M | |
| Investments | 1.7M | (14.5M) | (191.2M) | (6.3M) | 32.0M | 33.6M | |
| Net Borrowings | (3.2K) | (152.2K) | (63.7K) | (5.0M) | (4.5M) | (4.3M) | |
| Change To Netincome | 1.9M | 2.8M | 8.6M | 11.9M | 13.7M | 14.4M |
MaxCyte Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to MaxCyte or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that MaxCyte's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a MaxCyte stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.37 | |
β | Beta against Dow Jones | 1.56 | |
σ | Overall volatility | 3.19 | |
Ir | Information ratio | -0.09 |
MaxCyte Volatility Alert
MaxCyte exhibits very low volatility with skewness of -0.45 and kurtosis of 1.01. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure MaxCyte's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact MaxCyte's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.MaxCyte Fundamentals Vs Peers
Comparing MaxCyte's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze MaxCyte's direct or indirect competition across all of the common fundamentals between MaxCyte and the related equities. This way, we can detect undervalued stocks with similar characteristics as MaxCyte or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of MaxCyte's fundamental indicators could also be used in its relative valuation, which is a method of valuing MaxCyte by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare MaxCyte to competition |
| Fundamentals | MaxCyte | Peer Average |
| Return On Equity | -0.16 | -0.31 |
| Return On Asset | -0.11 | -0.14 |
| Profit Margin | (0.78) % | (1.27) % |
| Operating Margin | (1.72) % | (5.51) % |
| Current Valuation | 224.2 M | 16.62 B |
| Shares Outstanding | 105.48 M | 571.82 M |
| Shares Owned By Insiders | 1.49 % | 10.09 % |
| Shares Owned By Institutions | 70.51 % | 39.21 % |
| Number Of Shares Shorted | 3.24 M | 4.71 M |
| Price To Book | 1.76 X | 9.51 X |
| Price To Sales | 8.21 X | 11.42 X |
| Revenue | 41.29 M | 9.43 B |
| Gross Profit | 39.16 M | 27.38 B |
| EBITDA | (44.13 M) | 3.9 B |
| Net Income | (37.92 M) | 570.98 M |
| Cash And Equivalents | 240.89 M | 2.7 B |
| Cash Per Share | 2.37 X | 5.01 X |
| Total Debt | 18.74 M | 5.32 B |
| Debt To Equity | 0.06 % | 48.70 % |
| Current Ratio | 14.24 X | 2.16 X |
| Book Value Per Share | 2.03 X | 1.93 K |
| Cash Flow From Operations | (21.69 M) | 971.22 M |
| Short Ratio | 11.38 X | 4.00 X |
| Earnings Per Share | (0.34) X | 3.12 X |
| Target Price | 9.25 | |
| Number Of Employees | 143 | 18.84 K |
| Beta | 1.16 | -0.15 |
| Market Capitalization | 374.46 M | 19.03 B |
| Total Asset | 268.27 M | 29.47 B |
| Retained Earnings | (175.8 M) | 9.33 B |
| Working Capital | 172.34 M | 1.48 B |
| Net Asset | 268.27 M |
Note: Disposition of 47689 shares by Erck Stanley C of MaxCyte at 3.72 subject to Rule 16b-3 [view details]
MaxCyte Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as MaxCyte . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About MaxCyte Buy or Sell Advice
When is the right time to buy or sell MaxCyte? Buying financial instruments such as MaxCyte Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having MaxCyte in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Preferred Stock ETFs Thematic Idea Now
Preferred Stock ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Preferred Stock ETFs theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Preferred Stock ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.